George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Really some here have no understanding of what is happening with events but looking at motif with a very narrow and negative view ...that all about how to get funding while the big boys in the industry are taking serious look at Iclaprim in different applications of serious health importance.
Today rns is very significant in terms of outside research funding of Iclaprim in the treatment of Listeria and some posters here are thinking about the only 1600 cases reported cases in usa of none significant impact on Iclaprim ,but their ignorance of The Listeria infection in millions of pregnant women which the new research is showing the cause of early miscarriages (are caused by Listeria infection )and other problems too is causing in late pregnancy . These women are not showing signs clinically of Listeria infection but found later to be infected .This is why today rns is important and please try to post objective posts here which we all need rather than pathetic ones that bring negativity and confusion mingled with stupidity.
Be positive guys....motif will survive and flourish and ignore the trolls and losers here.
GL investors
Mate, did you have a shower this morning? Did you boil the kettle? Did you cross the road? All of these are risks, but we take them anyway to get something done, lol!
The risk here is (IMO), that mTFB would have to undertake a huge study and funding couldn't be found.
I don't think this is the case, but IVy is the guy to ask as he has been big source of correct information!
What great news, it’s ok at best. Can’t see no rise lol
Good morning!
It looks like MTFB is getting interest from other companies to fund initial studies.
Iclaprin is not dear (at all) and am inclined to think that once we know what needs doing, there will be many people putting their wallets out to offer to help or fund any additional studies.
FDA did not kill it and it just looks like an inconvenient to me and one that we could've done without, but am also sure that financing will become available and hopefully a few options!
Agree PrivateRyan. Some more grounded fact of our current situation would not go a miss.
Where are we with regards to financing and what current approach are we taking Ref FDA.
hardly a blockbuster with 1600 people infected in the states each year is it?and hence your predicted big jump does not occur- I am afraid your posts have as much balance as sp 250s....
An attempt at a pump to try and help get a funding round out. The company should be issuing an RNS on what the cash position is not this pointless dribble.
Great news..
Expect SP to jump in a big way following the news.
Listeria infection has 20% death rate currently and Iclaprim is showing a huge advantage on other Antibiotics currently used.